跳至主要内容
临床试验/NCT06388070
NCT06388070已完成3 期

A Multicenter, Randomized, Double-blinded, Non-inferiority Phase 3 Study to Evaluate the Efficacy and Safety of HUC3-053 Compared With Hyalein Mini Eye Drops in Patients With Dry Eye Syndrome

Huons Co., Ltd.1 个研究点 分布在 1 个国家目标入组 297 人开始时间: 2024年5月20日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
297
试验地点
1
主要终点
Change from Baseline in Corneal staining score

研究概览

简要总结

This is a multi-center, randomized, double-blinded, non-inferiority study to evaluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.

After a 2-week run-in period, patients will be randomized equally to the HUC3-053 or Hyalein Mini Eye Drops administered bilaterally five to six times a day for 12 weeks.

详细描述

This is a multi-center, randomized, double-blinded, non-inferiority study to evaluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.

During a 2-week study run-in period prior to randomization, all subjects will receive rescue drug bilaterally up to 4 times a day. Randomization will then occur as 1:1 where patients will be assigned to receive HUC3-053 or Hyalein Mini Eye Drops given bilaterally five to six times a day. The treatment period is 12 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 19
  • Volunteer who have had more than one symptom of dry eye disease for at least 3 month before screening visit.
  • Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 and OSDI (Ocular Surface Disease Index) ≥ 23 in at least one of both eyes
  • Best corrected visual acuity ≥ 0.2 in both eyes at Screening and Randomization Visit

排除标准

  • The patients with clinically significant ocular disorders affected the test result Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
  • SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c>9%
  • Wearing contact lenses within 72 hr of screening visit
  • Pregnancy or Breastfeeding

研究组 & 干预措施

HUC3-053

Experimental

Participants received "HUC3-053" in each eye five to six times a day for 12 weeks.

干预措施: HA 0.3% (Drug)

Hyalein Mini Eye Drops

Active Comparator

Participants received "Hyalein Mini Eye Drops" in each eye five to six times a day for 12 weeks.

干预措施: Hyalein Mini Eye Drops (Drug)

结局指标

主要结局

Change from Baseline in Corneal staining score

时间窗: Week 12

Change from Baseline in Corneal staining score at week 12

次要结局

  • Change from Baseline in Schirmer test(Week 4, 8, 12)
  • Change from Baseline in Corneal staining score(Week 4, 8)
  • Change from Baseline in Conjunctival staining score(Week 4, 8, 12)
  • Change from Baseline in Tear film break-up time(Week 4, 8, 12)
  • Change from Baseline in Eye Soreness after eye drop assessed by NRS(Week 4, 8, 12)
  • Change from Baseline in Ocular surface disease index(Week 4, 8, 12)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验